Fbxl17/spastin axis as a novel therapeutic target of hereditary spastic paraplegia

HIGHLIGHTS

• who: Hyun Mi Kang from the (UNIVERSITY) have published the paper: FBXL17/spastin axis as a novel therapeutic target of hereditary spastic paraplegia, in the Journal: (JOURNAL)
• what: Since SPAST Y52C mutant affected cell death and axonal outgrowth, the authors aimed to further dissect the pathophysiological implications of a deregulated FBXL17-SPAST axis.
• how: This result indicated that SPAST M1 is polyubiquitinated and degraded by the u00adSCFFBXL17 complex. Indicated that SPAST Y52C expression significantly reduced acetylated u03b1-tubulin levels similar to WT thus the authors confirmed that the SPAST Y52C mutation did not . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.